BTK and glioblastoma: Because CD163 expression predicts poor prognosis in GBM (51), we next used the immunohistochemical expression data of BTK (Figs 7, 9, and S5–S7) to determine whether BTK expression correlates with prognostic indicators, and whether it is similar to or distinct from CD163 as a predictor of poor prognosis.